New hope: shorter chemo combo for hodgkin lymphoma shows promise
NCT ID NCT07002216
First seen Nov 03, 2025 · Last updated May 08, 2026 · Updated 18 times
Summary
This study tests a shorter course of a drug combination called BrECADD for people with advanced Hodgkin lymphoma (stage 2B to IV). About 48 adults aged 18 to 60 will receive this treatment to see if it works well and is tolerable. Researchers will also check if a blood test for tumor DNA can help measure how well the treatment is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33146, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.